Why These Two Biotech ETFs Are Soaring Monday

ETF Trends

The PowerShares Dynamic Biotechnology & Genome Portfolio (PBE) and the SPDR S&P Biotech ETF (XBI) are up 8.4% and 6.8%, respectively, Monday, making the duo the day’s two best non-leveraged ETFs.

PBE and XBI are soaring because the two ETFs feature the largest weights among biotech funds to Idenix Pharmaceuticals (IDIX), shares of which have more than tripled today after Dow component Merkck(MRK) said it will acquire the company for $3.85 billion.

That values Idenix at $24.50 per share, nearly 3.5 times where the stock closed last Friday.

As of June 6 th , Idenix was PBE’s ninth-largest holding at a weight of 3%. No stock accounts for more than 5.15% of that ETF’s weight. Idenix is the fourteenth-largest holding in XBI with a weight of 1.46%. That does not sound like much, but XBI is an equal weight ETF where none of its 85 holdings receives an allocation north of 2.6%. [More Upside Possible for Biotech ETF]

Although it is an equal weight ETF, this is not the first time XBI has benefited in significant fashion from news pertaining directly to just one biotech stock. Earlier this year, the ETF surged more than 7% in one day after shares of Intercept Pharmaceuticals (ICPT) nearly quadrupled after trials for the company’s liver disease treatment proved successful. [Intercept Lifts This Biotech ETF]

The day those trial results were released, Intercept occupied just 1.6% of XBI’s weight.

Rivals to XBI and PBE, including the iShares Nasdaq Biotechnology ETF (IBB) and the First Trust NYSE Arca Biotechnology Index Fund (FBT) , f eature little to no exposure to Idenix. IBB, the largest biotech ETF, allocates 0.24% to Idenix while the stock is not a member of FBT’s portfolio.

The $499.9 million Market Vectors Biotech ETF (BBH) also does not feature Idenix among its holdings.

SPDR S&P Biotech ETF

View photo

.
xbi

 

ETF Trends editorial team contributed to this post

The opinions and forecasts expressed herein are solely those of Tom Lydon, and may not actually come to pass. Information on this site should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any product.

View Comments (0)